Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Lijiang Yinghua Biochemical and Pharmaceutical Co., Ltd.
WARNING LETTER
•Lijiang Yinghua Biochemical and Pharmaceutical Co., Ltd.•October 20, 2017

Lijiang Yinghua Biochemical and Pharmaceutical Co., Ltd. – FDA Warning Letter, Oct 20, 2017

Record Details

On April 19, 2018, the FDA issued a Warning Letter to Lijiang Yinghua Biochemical and Pharmaceutical Co., Ltd. following an inspection from October 16-20, 2017, which identified significant deviations from current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (API). This renders their API adulterated under section 501(a)(2)(B) of the FD&C Act.

Key violations include: 1. **Insufficient controls over computerized systems:** Laboratory equipment (HPLC, GC) lacked restricted access, with a single administrator username allowing all users to delete or modify files without an audit trail. This was a repeat deviation from a 2015 inspection. 2. **Failure to maintain complete data:** The firm could not provide electronic data from HPLC assay testing for API release, stability, and intermediate testing from September 2011 to May 2017, claiming accidental deletion. 3. **Failure to investigate deviations:** An HPLC injection for an intermediate stability sample showed an abnormal result, which was disregarded without documentation or investigation, and a subsequent "in-specification" injection was used for release. 4. **Quality unit failure to review and approve documents:** A Certificate of Analysis (COA) for an API batch was approved by the quality unit before all required testing was complete.

The FDA recommends retaining a qualified consultant for data integrity remediation. The firm must

Company
Lijiang Yinghua Biochemical and Pharmaceutical Co., Ltd.
Inspection date
October 20, 2017
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Joseph R. Lambert (Compliance Officer, CDER, Office of Manufacturing)
View Company Profile

ID · 6af133c1-b419-4253-985c-1349deb59d4c

Violation Codes4
21 U.S.C. 351(a)(2)(B)FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Lijiang Yinghua Biochemical and Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.